IDH1 and cholangiocarcinoma: For this reason, additional IDH1 inhibitors are under investigation in patients with CCA, including olutasidenib (FT-2102; NCT03684811), LY3410738 (NCT04521686), AB-218 (NCT05814536), and HMPL-306 (NCT04762602).